Moleculin Biotech, Inc.宣布在欧盟地区为其治疗急性髓系白血病的3期关键性Miracle试验首位患者进行给药治疗。
Moleculin Biotech, Inc.宣布在欧盟地区为其治疗急性髓系白血病的3期关键性Miracle试验首位患者进行给药治疗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.